TY - JOUR
T1 - Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type
AU - Yamamoto, M.
AU - Kuzuya, T.
AU - Baba, H.
AU - Yamada, K.
AU - Nabeshima, Toshitaka
PY - 2009/8
Y1 - 2009/8
N2 - Objective: To describe the population pharmacokinetics of vancomycin in patients with gram-positive infections and to investigate the influence of type of infectious disease. Methods: A two-compartment open model was adopted as a pharmacokinetic model. The nonlinear mixed-effects model was used to analyze the population pharmacokinetic models. Results: We propose one general model and one infectious disease type-specific model. The general model showed that vancomycin clearance (CL) was linearly correlated with estimated creatinine clearance (CLCR) when CLCR was less than 85 mL/min, as expressed by CL(L/h) = 0·0322 × CLCR + 0·32. The distribution volumes of the central and peripheral compartment were different in healthy volunteers and patients with gram-positive infections. The infectious disease type-specific model showed that these differences were more pronounced in patients with pneumonia. Conclusion: The population pharmacokinetic parameters of vancomycin obtained here can be used to individualize the dosage of vancomycin in institutions with similar patient population characteristics.
AB - Objective: To describe the population pharmacokinetics of vancomycin in patients with gram-positive infections and to investigate the influence of type of infectious disease. Methods: A two-compartment open model was adopted as a pharmacokinetic model. The nonlinear mixed-effects model was used to analyze the population pharmacokinetic models. Results: We propose one general model and one infectious disease type-specific model. The general model showed that vancomycin clearance (CL) was linearly correlated with estimated creatinine clearance (CLCR) when CLCR was less than 85 mL/min, as expressed by CL(L/h) = 0·0322 × CLCR + 0·32. The distribution volumes of the central and peripheral compartment were different in healthy volunteers and patients with gram-positive infections. The infectious disease type-specific model showed that these differences were more pronounced in patients with pneumonia. Conclusion: The population pharmacokinetic parameters of vancomycin obtained here can be used to individualize the dosage of vancomycin in institutions with similar patient population characteristics.
UR - http://www.scopus.com/inward/record.url?scp=67651253079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651253079&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2710.2008.01016.x
DO - 10.1111/j.1365-2710.2008.01016.x
M3 - Article
C2 - 19583681
AN - SCOPUS:67651253079
SN - 0269-4727
VL - 34
SP - 473
EP - 483
JO - Journal of Clinical Pharmacy and Therapeutics
JF - Journal of Clinical Pharmacy and Therapeutics
IS - 4
ER -